ATR

Rating neutralAI Memo

AptarGroup

As of 2026-07-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

CEO succession • 2026-09-01

Expected move: +6%

Biggest risk

Core sales were flat, adjusted EPS fell 8%, adjusted EBITDA margin declined to 19.2% from 20.7%, and emergency-medicine destocking plus operational and maintenance issues weighed on margins. Multiple officers also reported open-market sales in May and June. [#SEC-8K-2026-04-30] [#SEC-FORM4-2026-06-10]

Invalidation

Break below $112 or thesis failure.

What would change my mind?

Reported Q1 sales rose 11%, injectables grew 20%, Beauty core sales grew 3%, and management guided to Q2 adjusted EPS of $1.32-$1.40 with growth expected across segments outside emergency medicine. [#SEC-8K-2026-04-30]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-18

Base target

$140

p=50%

Bull target

$166

p=25%

Bear target

$112

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 2026 guidance execution
Destocking and margin pressure
Injectables, GLP-1 and Beauty demand

BearKey bullets

Analyst target count, estimate revisions, options data, short interest and direct operating peers are unavailable.
Emergency-medicine destocking and the 10% decline in Pharma prescription dispensing sales may persist.
Management flagged potential supply-chain uncertainties.

WatchKey bullets

CEO succession

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $140 (p=50%)

Bull/Bear spread: +25% / -16%

Vs latest close: Bull +25% · Base +6% · Bear -16%

Scenario probabilities

Bull Target: $166 (p=25%)Base Target: $140 (p=50%)Bear Target: $112 (p=25%)

Commentary

News tone is mixed: the primary Q1 release showed strong reported sales and injectables growth but flat core sales, lower earnings and margin compression, alongside constructive Q2 guidance. Recent dividend, sustainability and conference headlines add limited operating information. No social coverage, options skew, short interest, Glassdoor data, post-print price-reaction attribution or analyst revision data are available.

As of 2026-07-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 2026 guidance execution
Destocking and margin pressure
Injectables, GLP-1 and Beauty demand

Scenarios

Bull Target (Scenario probability)

$166 / p=25% prob

Base Target (Scenario probability)

$140 / p=50% prob

Bear Target (Scenario probability)

$112 / p=25% prob

Price $133 as of 2026-07-17

Nearest Scenario: Base (∆ 6%)

Targets vs latest close: Bull +25% · Base +6% · Bear -16%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-01
CEO succession
Gael Touya is scheduled to become CEO effective September 1, 2026. The transition is announced but execution and continuity remain monitoring points. [#SEC-8K-2026-04-30]
Prob 85.00% • Move 2.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Q2 2026 guidance execution
2026-10-16
Aptar guided to adjusted EPS of $1.32-$1.40 for Q2 2026 and expects growth across segments excluding emergency-medicine destocking, while flagging supply-chain uncertainty. [#SEC-8K-2026-04-30]
Prob 60% • Move 4% • Priced-in 55%
Destocking and margin pressure
2026-10-16
Emergency-medicine destocking reduced Pharma prescription sales, while adjusted EBITDA margins declined year over year in Pharma, Beauty and Closures. Further weakness or delayed recovery would pressure the shares. [#SEC-8K-2026-04-30]
Prob 65% • Move -5% • Priced-in 60%

Long-term Catalysts

Months to a year

Injectables, GLP-1 and Beauty demand
2027-07-18
Q1 injectables sales grew 20%, supported by GLP-1, biologics and antithrombotics, while Beauty core sales grew 3%; sustained demand could support recovery after near-term destocking. [#SEC-8K-2026-04-30]
Prob 55% • Move 8% • Priced-in 40%

Risks

Analyst target count, estimate revisions, options data, short interest and direct operating peers are unavailable.
Emergency-medicine destocking and the 10% decline in Pharma prescription dispensing sales may persist.
Management flagged potential supply-chain uncertainties.
Q1 adjusted EBITDA margin declined in all three segments, with mix, supplier disruption, maintenance issues, weather-related closures and write-offs cited as factors. [#SEC-8K-2026-04-30]
Several officers reported open-market stock sales in May and June; this supports caution but is not evidence of operating deterioration. [#SEC-FORM4-2026-06-10]
The September 2026 CEO transition creates an execution and continuity risk.

Peers

Symbol	Summary
GGB	Same-sector market-cap candidate, but steel exposure makes it a loose operating comparator rather than a direct Aptar peer.
MP	Same-sector market-cap candidate with rare-earths exposure; useful only for broad Materials sentiment, not operating comparison.
TX	Same-sector market-cap candidate with steel exposure; a loose valuation and sector reference.
BVN	Same-sector market-cap candidate with mining exposure; not a direct packaging or dispensing peer.
IAG	Same-sector market-cap candidate with gold-mining exposure; limited comparability to Aptar's business mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-18

AI Stock Memo: ATR - AptarGroup - RankAlpha